Can a Two-Drug combo help teens with severe mental illness?

NCT ID NCT07744113

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This expanded access program offers continued treatment with OLZ/SAM, a combination of olanzapine and samidorphan, to adolescents with schizophrenia or bipolar I disorder who have already completed a year-long study of the drug. The goal is to provide ongoing access to the medication while monitoring its safety and effectiveness in a real-world outpatient setting. Participants must have family support and be able to be treated as outpatients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
OLZ/SAM (olanzapine/samidorphan), a fixed-dose combination drug
What this could lead to
If successful, this program could offer a continued treatment option for adolescents with schizophrenia or bipolar I disorder, potentially improving symptom management and quality of life.
What could go wrong
This is an expanded access program, not a randomized trial, so it provides real-world data but no definitive efficacy conclusions. Risks include side effects from olanzapine, such as weight gain and metabolic changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR 1 DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alkermes Investigator Site

    AVAILABLE

    Miami, Florida, 33126, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.